Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Vaccines Market Insight: Products, Pipelines & Market Outlook

Published by: Informa Healthcare

Published: Sep. 1, 2007 - 175 Pages


Table of Contents


CHAPTER 1 INTRODUCTION
1.1 Vaccines
1.1.1 General
1.1.2 A brief history
1.2 The immune system
1.2.1 Introduction
1.2.2 MCH markers
1.2.3 Lymphocytes
1.2.4 B cells and T cells
1.2.5 Cytokines and chemokines
1.2.6 Phagocytes and granulocytes
1.2.7 Complement proteins
1.2.8 When the immune system fails
1.3 Immunological aspects of cancer
1.3.1 Introduction
1.3.2 The development of a tumour
1.3.3 The treatment of cancer
1.4 Immunisation
1.5 Types of vaccine
1.5.1 Prophylactic vaccines
1.5.2 Therapeutic vaccines
1.5.3 Recombinant vaccines
1.5.4 DNA vaccines
1.5.5 Autologous and allogenic vaccines
1.5.6 Attenuated live vaccines
1.5.7 Inactivated killed vaccines
CHAPTER 2 THE VACCINES MARKET
2.1 The vaccines market today
2.2 The potential for change
2.3 Market size
2.4 Major players
2.4.1 GlaxoSmithKline (GSK)
2.4.1.1 Company background
2.4.1.2 Products
2.4.1.3 Cervarix
2.4.1.4 Other cancer candidates
2.4.1.5 Other products in the pipeline
2.4.2 Merck & Co
2.4.2.1 Company background
2.4.2.2 Gardasil
2.4.2.3 Other launched products
2.4.2.4 Products in the pipeline
2.4.3 Novartis
2.4.3.1 Company background
2.4.3.2 Novartis' influenza vaccine pipeline
2.4.3.3 Other products in the pipeline
2.4.4 Sanofi-Aventis
2.4.4.1 Company background
2.4.4.2 Cancer vaccine products
2.4.4.3 Other vaccine products
2.4.5 Wyeth
2.4.5.1 Company background
2.4.5.2 Launched products
2.4.5.3 Products in the pipeline
2.5 The importance of cancer vaccines in the overall market
2.6 Marketed cancer vaccines
2.6.1 Cervarix - GlaxoSmithKline
2.6.2 Gardasil - Merck & Co
2.6.3 M-Vax - AVAX Technologies
2.6.4 TheraCys - Sanofi Pasteur
2.6.5 Bacillus Calmette-Guerin (BCG) vaccine - GSK
2.6.6 Melacine - GSK
2.7 Other marketed vaccines
2.7.1 Combination vaccinations
2.7.2 Hepatitis B
2.7.3 Hepatitis A
2.7.4 Influenza
2.7.4.1 FluMist - Aviron (now AstraZeneca)
2.7.4.2 Fluviron/Flu-Immune - Powderject Pharmaceuticals (now Novartis)
2.7.4.3 Fluviral - ID Biomedical (now GSK)
2.7.4.4 Fluzone - Sanofi Pasteur
2.7.4.5 Inflexal V and Nasalflu - Crucell
2.7.4.6 LAIV - The Institute of Experimental Medicine, St Petersburg, Russia
2.7.4.7 Other marketed influenza vaccines
2.7.5 Haemophilus influenzae type B (HiB)
2.7.6 Pertussis
2.7.7 Rabies
2.7.8 Typhoid
2.7.9 Varicella and zoster
2.7.10 Meningitis
2.7.10.1 Meningitis (non-specific)
2.7.10.2 Meningitis A
2.7.10.3 Meningitis B
2.7.10.4 Meningitis B/C
2.7.10.5 Meningitis C
2.7.11 Pneumococcus
2.7.12 Poliomyelitis
2.7.13 MMR and measles and rubella
2.7.14 Smallpox
2.7.15 Other indications
2.7.15.1 Cholera
2.7.15.2 Rotavirus
2.7.15.3 Epidemic haemorrhagic fever
2.7.15.4 Japanese encephalitis (JE)
2.7.15.5 Lactobacillus
2.7.15.6 Yellow fever
2.7.15.7 Tick borne encephalitis (TBE)
2.7.15.8 Q fever
2.7.15.9 Ribosomal vaccine
2.7.15.10 Urinary infection
2.7.16 Launched therapeutic vaccines
2.7.16.1 Leprovac
2.7.16.2 Fluarix
2.7.16.3 SolcoTrichovac
2.7.16.4 PCEC
2.7.17 Withdrawn vaccines
CHAPTER 3 CHALLENGES AND OPPORTUNITIES
3.1 Introduction
3.2 Unmet needs
3.2.1 Cancer
3.2.2 HIV/AIDS
3.2.3 Autoimmune diseases
3.2.3.1 Asthma
3.2.3.2 Diabetes mellitus (type 1)
3.2.3.3 Rheumatoid arthritis (RA)
3.2.4 Infectious disease
3.2.4.1 Tuberculosis (TB)
3.2.4.2 Meningitis
3.2.5 Malaria
3.2.6 Bioterrorism threat
3.2.7 Addiction
3.2.8 Hepatitis C (HCV)
3.2.9 CNS - Alzheimer's disease
3.3 Technical challenges
3.3.1 Alternatives to egg-grown vaccines
3.3.2 Alternatives to needles
3.3.3 Problems with supply and storage of vaccines
3.3.4 Reducing the number of vaccinations
3.4 Commercial challenges
3.4.1 Research and development
3.4.2 Economies of scale
3.4.3 Public opinion
CHAPTER 4 VACCINES IN DEVELOPMENT
4.1 Cancer
4.1.1 Introduction
4.1.2 Registered or awaiting approval
4.1.3 Cancer vaccines in Phase III clinical development
4.1.3.1 Brain cancer
4.1.3.2 HPV
4.1.3.3 Lung cancer and nsclc
4.1.3.4 Lymphoma
4.1.3.5 Pancreas cancer
4.1.3.6 Prostate cancer
4.1.3.7 Renal cancer
4.1.4 Cancer vaccines in Phase II clinical development
4.1.4.1 General
4.1.4.2 Brain cancer
4.1.4.3 Breast cancer
4.1.4.4 Cervical cancer
4.1.4.5 Colorectal cancer
4.1.4.6 Leukaemia
4.1.4.7 Lung cancer and nsclc
4.1.4.8 Lymphoma
4.1.4.9 Melanoma
4.1.4.10 Myeloma
4.1.4.11 Prostate cancer
4.1.4.12 Renal cancer
4.1.5 Cancer vaccines in Phase I clinical development
4.1.5.1 Multiple or unspecified targets
4.1.5.2 Bladder cancer
4.1.5.3 Brain cancer
4.1.5.4 Breast cancer
4.1.5.5 Head and neck cancer
4.1.5.6 Liver cancer
4.1.5.7 Lung and nsclc cancer
4.1.5.8 Oesophageal cancer
4.1.5.9 Ovarian and pancreatic cancers
4.1.5.10 Prostate cancer
4.1.6 Cancer vaccines in preclinical development
4.1.6.1 Non-specified cancers
4.1.6.2 General cancer targets
4.1.6.3 Bone cancer
4.1.6.4 Breast cancer
4.1.6.5 Colorectal and colon cancer
4.1.6.6 Gastric cancer
4.1.6.7 HPV
4.1.6.8 Leukaemia
4.1.6.9 Liver cancer
4.1.6.10 Lung cancer and nsclc
4.1.6.11 Melanoma
4.1.6.12 Myeloma
4.1.6.13 Ovarian cancer
4.1.6.14 Pancreatic cancer
4.1.6.15 Prostate cancer
4.1.6.16 Renal cancer
4.2 Infectious diseases
4.2.1 AIDS/HIV
4.2.1.1 The Aaron Diamond AIDS Research Center
4.2.1.2 Alphavax
4.2.1.3 Avant Immunotherapeutics
4.2.1.4 Bavarian Nordic
4.2.1.5 Bionor Immuno
4.2.1.6 Cytrx
4.2.1.7 Dong-A
4.2.1.8 EuroVac
4.2.1.9 FIT Biotech
4.2.1.10 Genecure
4.2.1.11 Genetic Immunity
4.2.1.12 Geovax
4.2.1.13 GlaxoSmithKline
4.2.1.14 Immunitor
4.2.1.15 Merck & Co
4.2.1.16 Neovacs
4.2.1.17 Novartis
4.2.1.18 Oxford Biomedica
4.2.1.19 Pharmexa
4.2.1.20 Powdermed
4.2.1.21 Sanofi-Aventis
4.2.1.22 St Jude's Hospital, Memphis
4.2.1.23 Targeted Genetics
4.2.1.24 Therion Biologics
4.2.1.25 The Vaccine Research Center (VRC)
4.2.1.26 Vaxgen
4.2.1.27 Vical
4.2.1.28 Virax
4.2.1.29 Virionics
4.2.1.30 Wyeth
4.2.1.31 Non-industry collaborations
4.2.2 Hepatitis (excluding paediatric combination vaccines)
4.2.2.1 Hepatitis B (HBV)
4.2.2.2 Hepatitis C (HCV)
4.2.2.3 Hepatitis E
4.2.3 Influenza
4.2.3.1 Acambis
4.2.3.2 Alphavax
4.2.3.3 Baxter
4.2.3.4 Crucell
4.2.3.5 CSL
4.2.3.6 Dynport Vaccine Company
4.2.3.7 Generex
4.2.3.8 GlaxoSmithKline
4.2.3.9 Iomai
4.2.3.10 Medimmune
4.2.3.11 Merck & Co
4.2.3.12 Nasvax
4.2.3.13 Novartis
4.2.3.14 Novavax
4.2.3.15 Powdermed
4.2.3.16 Protein Sciences
4.2.3.17 Sanofi-Aventis
4.2.3.18 Sinovac Biotech
4.2.3.19 Solvay
4.2.4 Malaria
4.2.5 Meningitis and pneumococcal infection
4.2.5.1 China Biopharma
4.2.5.2 Emergent Biosolutions
4.2.5.3 GlaxoSmithKline
4.2.5.4 LG Life Sciences
4.2.5.5 Novartis
4.2.5.6 Sanofi-Aventis
4.2.5.7 Wyeth
4.2.6 Tuberculosis
4.2.7 Other infectious diseases
4.2.7.1 Cholera
4.2.7.2 Dengue fever
4.2.7.3 Ebola and Marburg infections
4.2.7.4 Helicobacter pylori
4.2.7.5 Japanese encephalitis
4.2.7.6 Rabies
4.2.7.7 Rotavirus
4.2.7.8 Typhoid fever
4.2.7.9 West Nile virus infection
4.2.7.10 Yellow fever
4.3 Other indications
4.3.1 Addiction
4.3.2 Allergy and asthma
4.3.3 Autoimmune diseases
4.3.3.1 Diabetes
4.3.3.2 Rheumatoid arthritis (RA)
4.3.4 Bioterrorist threats
4.3.4.1 Anthrax
4.3.4.2 Botulinum
4.3.4.3 Plague
4.3.4.4 Smallpox
4.3.5 Alzheimer's disease
4.3.6 Obesity
CHAPTER 5 COMPANY PROFILES
5.1 Introduction
5.2 Ęterna Zentaris
5.2.1 Company overview
5.2.2 Financial data
5.2.3 Products
5.2.4 R&D portfolio
5.3 Argos Therapeutics
5.3.1 Company overview
5.3.2 Financial data
5.3.3 Products
5.3.4 R&D portfolio
5.4 Avant Immunotherapeutics
5.4.1 Company overview
5.4.2 Financial data
5.4.3 Products
5.4.4 R&D portfolio
5.5 AVAX TECHNOLOGIES
5.5.1 Company overview
5.5.2 Financial data
5.5.3 Products
5.5.4 R&D portfolio
5.6 BT Pharma
5.6.1 Company overview
5.6.2 Financial data
5.6.3 Products
5.6.4 R&D portfolio
5.7 Bavarian Nordic
5.7.1 Company overview
5.7.2 Financial data
5.7.3 R&D portfolio
5.8 Baxter International
5.8.1 Company overview
5.8.2 Financial data
5.8.3 Products
5.8.4 R&D portfolio
5.9 Cancer Research Technology
5.9.1 Company overview
5.9.2 Financial data
5.9.3 Products
5.9.4 R&D portfolio
5.10 Cell Genesys
5.10.1 Company overview
5.10.2 Financial data
5.10.3 Products
5.10.4 R&D portfolio
5.11 Cellgenix Technologie Transfer
5.11.1 Company overview
5.11.2 Financial data
5.11.3 Products
5.11.4 R&D portfolio
5.12 Celtic Pharma
5.12.1 Company overview
5.12.2 Financial data
5.12.3 Products
5.12.4 R&D portfolio
5.13 Crucell
5.13.1 Company overview
5.13.2 Financial data
5.13.3 Products
5.13.4 R&D portfolio
5.14 CSL
5.14.1 Company overview
5.14.2 Financial data
5.14.3 Products
5.14.4 R&D portfolio
5.15 Cytos Biotechnology
5.15.1 Company overview
5.15.2 Financial data
5.15.3 Products
5.15.4 R&D portfolio
5.16 Dendreon
5.16.1 Company overview
5.16.2 Financial data
5.16.3 Products
5.16.4 R&D portfolio
5.17 FIT Biotech
5.17.1 Company overview
5.17.2 Financial data
5.17.3 Products
5.17.4 R&D portfolio
5.18 Generex
5.18.1 Company overview
5.18.2 Financial data
5.18.3 Products
5.18.4 R&D portfolio
5.19 Geron
5.19.1 Company overview
5.19.2 Financial data
5.19.3 Products
5.19.4 R&D portfolio
5.20 Immunocellular Therapeutics
5.20.1 Company overview
5.20.2 Financial data
5.20.3 Products
5.20.4 R&D portfolio
5.21 Immunofrontier
5.21.1 Company overview
5.21.2 Financial data
5.21.3 Products
5.21.4 R&D portfolio
5.22 Immunomedics
5.22.1 Company overview
5.22.2 Financial data
5.22.3 Products
5.22.4 R&D portfolio
5.23 Immunotope
5.23.1 Company overview
5.23.2 Financial data
5.23.3 Products
5.23.4 R&D portfolio
5.24 Immvarx
5.24.1 Company overview
5.24.2 Financial data
5.24.3 Products
5.24.4 R&D portfolio
5.25 Juvaris Biotherapeutics
5.25.1 Company overview
5.25.2 Financial data
5.25.3 Products
5.25.4 R&D portfolio
5.26 Molmed
5.26.1 Company overview
5.26.2 Financial data
5.26.3 Products
5.26.4 R&D portfolio
5.27 Mologen
5.27.1 Company overview
5.27.2 Financial data
5.27.3 Products
5.27.4 R&D portfolio
5.28 Neovacs
5.28.1 Company overview
5.28.2 Financial data
5.28.3 Products
5.28.4 R&D portfolio
5.29 Newlink Genetics
5.29.1 Company overview
5.29.2 Financial data
5.29.3 Products
5.29.4 R&D portfolio
5.30 Oxford Biomedica
5.30.1 Company overview
5.30.2 Financial data
5.30.3 Products
5.30.4 R&D portfolio
5.31 Pepscan Systems
5.31.1 Company overview
5.31.2 Financial data
5.31.3 Products
5.31.4 R&D portfolio
5.32 Progenics Pharmaceuticals
5.32.1 Company overview
5.32.2 Financial data
5.32.3 Products
5.32.4 R&D portfolio
5.33 Targepeutics
5.33.1 Company overview
5.33.2 Financial data
5.33.3 Products
5.33.4 R&D portfolio
5.34 Therion Biologies
5.34.1 Company overview
5.34.2 Financial data
5.34.3 Products
5.34.4 R&D portfolio
5.35 Vaxon Biotech
5.35.1 Company overview
5.35.2 Financial data
5.35.3 Products
5.35.4 R&D portfolio
5.36 Virionics
5.36.1 Company overview
5.36.2 Financial data
5.36.3 Products
5.36.4 R&D portfolio


Abstract

This report examines the latest developments in the vaccine industry with particular emphasis placed on the role of vaccines in the prevention and treatment of cancer. It includes an overview of the immune system, an outline of how immunisation works and an assessment of how different types of vaccine work with that system. The report looks in particular at the suitability of cancer as a target for the next generation of vaccines.

The report examines the size and value of the vaccine market as it is today. This includes a full discussion of the vaccines that have reached the marketplace, including the first cancer vaccines. The vaccine market is currently dominated by a handful of pharmaceutical companies and these are also discussed.

The vaccine industry faces numerous opportunities as its understanding of the immune system grows, increasing both the number of vaccines in development and the range of suitable indications to target. However, there are also serious challenges that must be overcome: developers and manufacturers face technical and commercial challenges.

The report includes a full discussion of the many vaccines currently in development, focusing on those for cancer and for other unmet needs. The report concludes with profiles of the pharmaceutical and biotechnology companies that are actively developing cancer vaccines, as well as the major players in the vaccine market as a whole.

The report provides:
  • an overview of the immune system
  • enables an understanding of how vaccines have worked in the past and how an increasing knowledge of how
  • the immune system works is affecting the types of vaccine currently in development.
  • a discussion of the immunological aspects of cancer
  • a summary of the types of vaccines available
  • a discussion of the vaccines market
  • how important cancer vaccines are and an assessment of the size of the market
  • a complete guide to the current vaccines on the market
  • background on the indications targeted by these vaccines and the companies that develop them
  • study of the major players in the market
  • review of the technical and commercial challenges
  • how to overcome the difficulties associated with vaccination
  • full study of the vaccines in development
  • profiles of 40 companies actively involved in the development of cancer vaccines



Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009